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Synopsis
Coronary artery disease is treated by vein grafting and stent implantation. Late vein graft failure and restenosis of
stented arteries reduce the success rates of these approaches and are caused by neointima formation. We have
previously shown that Wnt proteins are up-regulated during intimal thickening, and have speculated that these lead
to activation of downstream genes with β -catenin/T-cell factor (TCF)-responsive promoters. In the present study, we
aimed to provide evidence that β -catenin/TCF signalling promotes neointima formation and assess whether targeting
this pathway has potential for reducing neointima formation. We utilized a gene therapy approach selectively targeting
cells in which the β -catenin/TCF pathway is activated by using a recombinant adenovirus Ad-TOPTK, which carries a
herpes simplex virus thymidine kinase (HSV-TK) gene under the control of a β -catenin/TCF-response promoter. Cells
with activated β -catenin will therefore be selectively killed. Ad-TOPTK and ganciclovir (GCV) treatment significantly
suppressed the growth of the neointima in a murine model of left carotid artery ligation. In summary, we demonstrated
that Wnt/β -catenin/TCF signalling promotes neointima formation, by showing that the selective death of cells with
activated β -catenin suppressed neointima formation. This highlights the therapeutic potential for reducing late vein
graft failure and in-stent restenosis by targeting β -catenin/TCF signalling.
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INTRODUCTION
Migration and proliferation of vascular smooth muscle cells (VS-
MCs) to form a neointima occur in pathologies such as restenosis
after angioplasty and vein grafting. Our recent work has shown
the involvement of the Wnt/β-catenin pathway in both migration
[1,2] and proliferation [3]. This has been confirmed by work in
other groups [4–6]. However, it has never been shown directly
that β-catenin/T-cell factor (TCF) signalling is directly required
for neointima formation in vivo.
We aimed to show that β-catenin/TCF signalling is required
for neointima formation and to examine whether using a suicide
gene approach, similar to that previously utilized by Kwong et
al. [7] in a mouse model of colon cancer, could retard neoin-
tima formation following complete carotid artery ligation in
mice. To achieve this, we have utilized an adenoviral vec-
tor in which expression of the herpes simplex virus thymidine
kinase (HSV-TK) gene is driven by a novel β-catenin/TCF-
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responsive promoter linked to a minimum CMV promoter (Ad-
TOPTK). We delivered this adenovirus to the adventitia of
the mouse carotid artery after ligation and then implanted a
mini-osmotic pump to infuse ganciclovir (GCV). If the ca-
rotid ligation and induction of neointima formation resulted
in increased β-catenin signalling, this would lead to produc-
tion of thymidine kinase (TK) by the TOPTK virus. Expres-
sion of TK would in turn convert the inactive prodrug GCV
(9-[2-hydroxy-1-(hydroxyethoxy)ethoxy]methylguanine; GCV)
into toxic GCV triphosphate resulting in the selective death of
cells with β-catenin activity, and thereby reducing neointima
formation.
In summary, the present study will not only test directly
whether β-catenin/TCF signalling is required for neointima form-
ation but also be a proof of principle study to demonstrate whether
a β-catenin /TCF signalling driven suicide gene approach retards
neointima formation. If this is the case, future approaches could
be developed to utilize this strategy to reduce vein graft failure
and in-stent restenosis.
c© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
Licence 4.0 (CC BY).
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MATERIALS AND METHODS
Adenoviruses
Ad-TK and Ad-TOPTK viruses were generously provided by
Mien-Chie Hung (Department of Molecular and Cellular On-
cology, MD Anderson Cancer Center, The University of Texas,
Houston, Texas). These viruses have been described in detail
previously [7]. Production of Ad-β-galactosidase (Ad-β-gal) [8]
and Ad-m-β-cat (encoding constitutively active β-catenin) have
been described previously [9].
Human VSMC culture and infection
Surplus de-identified segments of human saphenous vein were
collected at the completion of bypass surgery from patients that
gave written informed consent for the use of their tissues for
research. The use of these vein segments for the present study
was approved by NHS National Research Ethics Service (NRES
number 04/Q2007/6: Frenchay Ethics Research Committee). It
was not necessary for the Faculty of Health Sciences Ethics
Board, University of Bristol to approve the present study as
it was approved by NRES. However, the University of Bris-
tol Research Governance approved, registered and sponsored
the present study. Human saphenous vein smooth muscle cells
(SMCs) were isolated from the saphenous vein segments using
the explant technique [10] and maintained in Dulbecco’s Mod-
ified Eagle’s medium supplemented with 10% (v/v) FBS and
antibiotics. Cells were utilized between passages two and six.
Cells were infected at ∼70% confluency. An accurate cell count
was performed prior to infection. Cells were infected with 1000
plaque forming units (pfu)/cell of Ad-TK, Ad-TOPTK or Ad-β-
gal with or without 300 pfu/cell Ad-m-β-cat or Ad-β-gal for 18 h
in complete media. Subsequently, cells were washed with PBS
and cultured for a further 64 h in fresh serum-free media in the
presence or absence of 10 μg/ml GCV. To quantify cell number,
cells were analysed using the water-soluble tetrazolium (WST)
assay. In brief, WST-1 reagent (Roche Molecular Biochemic-
als) was added to cells following the manufacturer’s instructions,
incubated at 37 ◦C for 2 h and then the absorbance at 450 nm
measured to quantify cell number.
Husbandry
C57bl6/J mice were obtained and housed in the animal facilities
at the University of Bristol. Housing, care and all procedures
were performed in accordance with the guidelines and regula-
tions of the University of Bristol and the United Kingdom Home
Office. The investigation conforms to the Guide for the Care and
Use of Laboratory Animals published by the US National Insti-
tutes of Health (NIH Publication No. 85-23, revised 1996). The
University of Bristol, Animal Welfare and Ethical Review Body
(AWERB) approved the present study. The left common carotid
artery was ligated near the carotid bifurcation, as described previ-
ously [3], to induce neointima formation. Following the ligation,
the artery was surrounded by 30% (w/v) pluronic gel containing
0.44 × 1010 pfu Ad-β-gal, Ad-TK or Ad-TOPTK adenovirus. An
osmotic mini-pump (Catalogue number 2002 and 2004, Alzet)
was inserted subcutaneously that released GCV at 25 mg/kg per
day or PBS as control.
Histochemistry and immunohistochemistry
The ligated carotid arteries were removed 3 and 21 days later
and embedded in agar blocks vertically or horizontally respect-
ively for sectioning. Agar blocks were processed and embedded
in paraffin wax. Sections were cut at 3 μm thickness and stained
using elastin Van Gieson (EVG) for visualization and quantific-
ation of the vessel and neointima by image analysis (Image Pro).
The size of the intima was measured and then expressed as a
percentage of the lumen area. Immunofluorescence staining for
TK was performed using 4 μg/ml goat anti-HSV-1 TK (Santa
Cruz Biotechnology: VN-20 SC-20837) to show expression of
the virus following adenoviral infection and ligation. Briefly,
sections were deparaffinized, rehydrated and subjected to anti-
gen retrieval using citrate buffer and microwaving, sections were
blocked with Image-FX and then incubated with the primary an-
tibody overnight. The following day the bound primary antibody
was detected with anti-goat Alexa Fluor-488 and then mounted
with prolong gold with DAPI. Non-immune goat IgG was used
as negative control.
Western blotting
Carotid arteries were removed, rinsed in PBS, chopped finely
and lysed in 5% (w/v) SDS lysis buffer with agitation for 15 min,
before centrifugation at 13.000 g for 5 minutes and removal of
supernatant for Western blotting using 50 ng/ml goat anti-HSV-
1 TK (Santa Cruz Biotechnology: VN-20 SC-20837). Bound
primary antibodies were detected using HRP-conjugated second-
ary antibodies and ECL reagent (GE Healthcare). Protein loading
was observed using Bio-Rad stain-free technology.
Statistics
Results are expressed as mean +− S.E.M. Data were analysed by
ANOVA and Student–Newman–Keuls post hoc test when more
than three groups were analysed and Student’s t test when two
groups were analysed. A significant difference accepted when
P < 0.05.
RESULTS
Selective killing of VSMC with β-catenin signalling
In order to test the hypothesis that VSMCs can be selectively
killed by targeting β-catenin/TCF pathway with a responsive pro-
moter, VSMCs were infected with Ad-TOPTK with or without
Ad-β-catenin and cultured in the presence or absence of GCV.
Cell number was measured by WST-1 assay, to assess cell vi-
ability. The efficacy of Ad-TOPTK in cell killing was compared
with the adenovirus with TK under the control of the complete
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Figure 1 VSMCs with increased levels of active β-catenin are selectively killed by Ad-TOPTK
Human saphenous vein VSMCs were infected with 1000 pfu/cell Ad-TK, Ad-β -gal, Ad-TOPTK with or without 300 pfu/cell
Ad-β -gal or Ad-β -catenin and cultured in the presence or absence of GCV. Cell number was measured by WST-1 and the
% of control without GCV was calculated. n=3, * indicates significant difference from no virus, Ad-β -gal, Ad-TOPTK and
Ad-TOPTK + Ad-β -gal, ANOVA and Student–Newman–Keuls post hoc test.
Figure 2 Expression of TK in the carotid artery after application of Ad-TK and Ad-TOPTK
Ligated carotid arteries (n=4 per group) were coated with pluronic gel containing Ad-TK or Ad-β -gal as control. After
3 days, the arteries were subjected to either immunofluorescence for TK (A) or Western blotting for TK (B). Ligated carotid
arteries (n=4 per group) were coated with pluronic gel containing Ad-TOP-TK or Ad-β -gal as control. After 3 days, the
arteries were subjected to immunofluorescence for TK (C). TK is stained green and nuclei are stained blue with DAPI in
immunofluorescence (A and C). Negative control arteries infected with Ad-TOPTK were subjected to immunofluorescence
using non-immune immunoglobulin (C). Scale bar represents 20 μm and applies to both IHC panels.
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Figure 3 Effect of Ad-TOPTK/GCV on neointima formation
Representative examples of EVG stained sections of carotid arteries infected with Ad-TOPTK without GCV treatment
(A: n=8) and Ad-TOPTK with GCV treatment (B: n=10). Scale bar represents 200 μm and applies to both panels. Intimal
area (C) and percentage of occlusion of the artery (D) were quantified. *indicates P<0.05 compared with control without
GCV, Student’s t test.
CMV promoter (Ad-TK). As shown in Figure 1, almost all cells
subjected to infection with Ad-TK and cultured in the presence
of GCV were killed. Infection with Ad-β-gal, Ad-TOPTK or Ad-
TOPTK + Ad-β-gal and culture in the presence of GCV had no
significant effect on cell death (Figure 1). In contrast, cell death
was significantly increased in VSMCs infected with Ad-TOPTK
+ Ad-β-catenin compared with uninfected cells and VSMCs in-
fected with Ad −β-gal, Ad-TOPTK or Ad-TOPTK + Ad-β-gal
(Figure 1). This result indicated that in the presence of GCV, the
adenoviral vector Ad-TOPTK could selectively induce death in
VSMCs with enhanced β-catenin signalling. These results indic-
ated that Ad-TOPTK plus GCV treatment could be used in gene
therapy to selectively kill VSMC without affecting VSMCs basal
levels of β-catenin signalling.
Infection of carotid artery with adenoviruses
The effectiveness of infecting the carotid artery of mice with ad-
enoviruses using pluronic gel was examined using the Ad-TK
and Ad-TOPTK virus; Ad-β-gal was used as a negative control.
The virus was applied to the adventitia immediately after lig-
ation in pluronic gel. The animal was allowed to recover and
3 days later the carotid arteries were removed. Arteries were
either fixed in formalin and subjected to immunofluorescence for
TK or chopped finely and lysed in 5% SDS lysis buffer. Figure 2
illustrates that TK protein was detected by both immunofluor-
escence (Figure 2A) and Western blotting (Figure 2B) in the
ligated artery, whereas it was undetectable in arteries infected
with Ad-β-gal.
Activation of β-catenin after carotid ligation
To demonstrate activation of the β-catenin signalling pathway
after carotid ligation, Ad-TOPTK was delivered to the adventi-
tia of ligated carotid arteries using pluronic gel. Ad-β-gal was
used as a negative control. Figure 2(C) illustrates that follow-
ing application of Ad-TOPTK virus, TK protein was detected
in the ligated artery, whereas it was undetectable in arteries in-
fected with Ad-β-gal. This shows that β-catenin/TCF activity
in the vessel following carotid ligation was sufficient to activate
expression of TK via the TOP promoter.
Suppression of neointima formation by
Ad-TOPTK/GCV
To test the effectiveness of Ad-TOPTK/GCV in suppressing
neointima formation in animals, the adenovirus was delivered
to the adventitia of ligated carotid arteries using pluronic gel.
In addition, these animals received mini-osmotic pumps to con-
tinuously deliver GCV for 21 days and the size of the neoin-
tima was measured from paraffin wax embedded sections. As
shown in Figure 3, Ad-TOPTK virus with GCV treatment sup-
pressed neointima formation and occlusion of the carotid artery.
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Figure 4 Schematic representation of the reduction in neointima formation by Ad-TOPTK adenovirus and GCV treatment
Carotid ligation leads to activation of β -catenin/TCF signalling in the presence of Ad-TOPTK and GCV, this leads to the
production of TK that converts GCV into toxic GCV-triphosphate. This leads to ‘suicide’ of cells and reduction in neointima
formation as a result of β -catenin/TCF signalling.
These results were consistent with the hypothesis that suicide
gene expression driven by the β-catenin/TCF-sensitive TOP pro-
moter can effectively suppress neointima formation. GCV alone
did not affect intima size or occlusion (19905 +− 3856 compared
with 23255 +− 5328 μm2 and 63 +− 12 compared with 77 +− 8%
respectively).
DISCUSSION
The present study shows that selective death of cells with ac-
tivated β-catenin can reduce neointima formation in vivo. Al-
though previous studies have implied the involvement of this
pathway using reporter animals, detection of β-catenin activity
and up-regulation of β-catenin target genes [3,4,11]; direct evid-
ence demonstrating a causal role of β-catenin/TCF signalling in
neointima formation has not been reported. It was important to
gather this evidence as β-catenin activity alone does not conclus-
ively demonstrate a causal role in disease, as previously noted by
Marchand et al. [12]. Furthermore, identification of a causal role
highlights the possibility of future therapeutic approaches aimed
at targeting this pathway. This strategy could be potentially util-
ized to retard intimal thickening in vein grafts and stented arteries
and thereby reduce failure rates of these two techniques.
When embarking on the present study, we considered the β-
catenin/TCF signalling pathway as a very promising approach
due to the expanding evidence that was suggestive of a role for
β-catenin/TCF signalling in neointima formation. β-catenin is
usually sequestered at the cell membrane by N-cadherin, where
it is a component of the cadherin cell–cell contacts. During cell
migration and proliferation, we have shown that the cell–cell
contacts are lost, N-cadherin is shed from the cell extracellular
membrane by proteases including matrix degrading metallopro-
teinases, and β-catenin is released into the cell [10,13]. This free
β-catenin is then able to act as a signalling molecule, so in the
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presence of Wnt proteins it can lead to activation of TCF/LEF
and therefore changes in gene expression including up-regulation
of cyclin D1 and down-regulation of p21 [1–3]. Moreover, our
group has shown in vivo, using TOPgal transgenic mice that β-
catenin activity is increased in the media of left carotid arteries
3 days after carotid ligation injury and in the neointima formed
28 days after injury [9].
The present study uses a targeted cell death approach, which
has been successfully utilized by groups working in cancer bio-
logy [7,14–16]. It is well established that β-catenin/TCF sig-
nalling plays a role in cancer cell proliferation [14], and con-
sequently targeting this pathway has been previously utilized to
suppress tumour growth [7,15,16], but this approach has not pre-
viously been applied to a cardiovascular disease model. Kwong
et al. [7] used the same approach as utilized in our study to show
that colon cancer was suppressed in mice given Ad-TOPTK/GCV.
Similarly, suppressed colon cancer growth was observed in mice
treated with adenovirus overexpressing the apoptosis inducer
p53-up-regulated modulator of apoptosis (PUMA) under the con-
trol of the TOP promoter [15]. Although Chen and McCormick
[16] demonstrated a similar gene therapy strategy targeting colon
cancer by a β-catenin/TCF-response promoter driving the ex-
pression of the pro-apoptotic gene Fadd. Beneficial effects have
also been observed by inhibition of proliferation of pancreatic
and gastric cancer cells using the β-catenin promoter to drive the
expression of suicide genes [17,18].
Although it is unlikely to be feasible to directly translate this
approach to humans due to the requirement for continual GCV
infusion, we consider that this proof of principle study was crit-
ical to provide the foundation to examine other suicide gene
approaches for the use in restenosis and late vein graft failure.
Accordingly, future approaches should avoid the requirement for
GCV in order to be useful therapeutics. In addition, it is import-
ant that the suicide gene chosen for future work is not secreted,
to ensure containment of the cell death to only cells with β-
catenin/TCF signalling and not within non-activated cells in the
close vicinity. Further work is needed to investigate the effect this
approach has on endothelial cell function since this is an import-
ant mediator of neointima formation. Wnt/β-catenin signalling
is known to affect endothelial cell migration and proliferation
[19], so it is essential to demonstrate that targeting this pathway
is not detrimental to endothelial cell survival or function, for it
to be a useful therapy. It is well established that other signalling
pathways such as Erk/Ras/Mek also regulate neointima formation
[19], but our study illustrates that selective induction of cell death
in cells through activation of a suicide gene by β-catenin/TCF
signalling is sufficient to attenuate neointima formation.
In conclusion, we have demonstrated that β-catenin/TCF sig-
nalling was activated within the neointima of ligated arteries. We
also showed that the combination of Ad-TOPTK adenovirus and
GCV treatment selectively killed β-catenin-activated cells, both
in tissue culture and in an in vivo animal model (summarized in
Figure 4). Thus, our work demonstrates that this approach may
have therapeutic potential for the reduction in neointima form-
ation and thereby may attenuate the failure rate of vein grafts
and stented arteries. In the long term, this may improve the suc-
cess rates of treatments used for patients with coronary artery
disease.
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